Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) EBIAT (2020 - 2025)

Historic EBIAT for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$5.5 million.

  • Cytek Biosciences' EBIAT fell 68214.67% to -$5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.8 million, marking a year-over-year decrease of 2619.35%. This contributed to the annual value of -$6.0 million for FY2024, which is 5044.45% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' EBIAT is -$5.5 million, which was down 68214.67% from -$5.6 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' EBIAT peaked at $9.6 million during Q4 2024, and registered a low of -$11.4 million during Q1 2025.
  • For the 5-year period, Cytek Biosciences' EBIAT averaged around -$1.8 million, with its median value being -$1.2 million (2021).
  • The largest annual percentage gain for Cytek Biosciences' EBIAT in the last 5 years was 41914.16% (2022), contrasted with its biggest fall of 221568.63% (2022).
  • Over the past 5 years, Cytek Biosciences' EBIAT (Quarter) stood at -$1.2 million in 2021, then surged by 419.14% to $3.7 million in 2022, then soared by 48.01% to $5.5 million in 2023, then surged by 75.23% to $9.6 million in 2024, then tumbled by 156.81% to -$5.5 million in 2025.
  • Its last three reported values are -$5.5 million in Q3 2025, -$5.6 million for Q2 2025, and -$11.4 million during Q1 2025.